Catalyst Wire Dossier Catalyst Wire Dossier

ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)

· CanSino Biologics Inc.
Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector), covering 2025-07-03 to 2026-03-04. Get the full timeline:

Most recent: Clinical Trial Update: Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) [Phase 4]

See pricing